Area of research
Obstetrics and Gynecology · Reproductive Medicine
Research interest
Research focused on Olaparib and Cancer research, with related work in Apoptosis, Gene knockdown, Tolerability. Notable publications include 'Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort', 'Guanosine monophosphate synthase upregulation mediates cervical cancer progression by inhibiting the apoptosis of cervical cancer cells via the Stat3/P53 pathway', and 'Prophylactic intraoperative uterine or internal iliac artery embolization in planned cesarean for pernicious placenta previa in the third trimester of pregnancy'.
The efficacy and safety of tislelizumab plus bevacizumab and chemotherapy as first line therapy in patients with persistent, recurrent, or metastatic cervical cancer: A multicenter, phase II study.
Olaparib maintenance monotherapy in Chinese patients with platinum‐sensitive relapsed ovarian cancer: China cohort from the phase III SOLO2 trial
Guanosine monophosphate synthase upregulation mediates cervical cancer progression by inhibiting the apoptosis of cervical cancer cells via the Stat3/P53 pathway
Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort
Prophylactic intraoperative uterine or internal iliac artery embolization in planned cesarean for pernicious placenta previa in the third trimester of pregnancy
Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort.
Analysis of HGF, MACC1, C-met and apoptosis-related genes in cervical carcinoma mice